Genetic studies have revealed a role for the transforming growth factor beta (TGFb) superfamily growth factors in development of the mouse kidney. In this study, we have characterized developmental expression of Smad proteins, the downstream effectors of TGFb superfamily ligands. Immunohistochemistry detecting Smads 1-5 and 8 was performed on 11.25-15.5 dpc kidney sections. We find that Smad proteins are readily detected in metanephric mesenchyme but are coordinately down-regulated in condensing mesenchyme and derivative structures such as renal vesicles. In order to define the stage at which down-regulation occurs, we used the heterologous inducer lithium chloride to promote condensation in isolated cultured mesenchymal explants and subsequently assayed expression of Smad 4. Downregulation is complete in lithium chloride induced mesenchymal condensates, indicating that Smad regulation takes place at an early stage, prior to mesenchyme to epithelium transition. q
The formation of the metanephric kidney is initiated by growth of the ureteric bud into the metanephric mesenchyme, a caudal segment of intermediate mesoderm. After initial contact, a reiterated inductive program takes place whereby branches derived from the ureteric bud induce condensation and epithelialization of adjacent metanephric mesenchyme to initiate formation of nephrons (Saxen, 1987) . The mesenchyme in its turn promotes directional growth of the ureteric bud branches, known during later stages of kidney development as collecting ducts. In addition to the ureteric bud and metanephric mesenchyme, the peripheral stroma is required for kidney morphogenesis. Mutations of genes expressed uniquely in this cell population have revealed a function for the peripheral stroma in directing the developmental program of nephrogenesis through paracrine signals that influence both collecting duct and metanephric mesenchyme morphogenesis (Hatini et al., 1996; Mendelsohn et al., 1999; Batourina et al., 2001) .
Gene targeting studies have indicated an important involvement of the transforming growth factor beta (TGFb) superfamily of signaling molecules, particularly the bone morphogenetic proteins (BMPs), in the formation of the metanephros. Mice homozygous for loss of function mutations in BMP7 complete the initial inductive program leading to the formation of a number of epithelial structures destined to become nephrons. However, as development of the metanephros progresses, the nephrogenic zone is prematurely depleted and reduced numbers of nephrons are formed (Dudley et al., 1995; Luo et al., 1995) .
BMPs are synthesized in structures including the nascent nephrons and collecting ducts. The nephrogenic mesenchyme exclusively expresses BMP7. TGFb ligands are expressed in collecting ducts and nascent epithelial structures, but excluded from the mesenchyme (Pelton et al., 1991) . Previous studies have documented expression patterns of TGFb and BMP receptors in the developing kidney (Pelton et al., 1991; Dudley and Robertson, 1997; Mariano et al., 1998; Raatikainen-Ahokas et al., 2000) . Receptors for the BMPs appear to be widely expressed, in contrast to the TGFb receptors which are limited to the epithelial structures of the kidney. Little is, however, known about expression of Smad signal transduction mediators downstream of the receptors, and thus which cells are competent to respond to BMP and TGFb signaling. In this study, we have taken advantage of antibody reagents specific for the Smad proteins to perform immunohistochemistry on paraffin-embedded kidney sections (Flanders et al., 2001) .
In order to assess the dynamics of Smad expression around the time of initial induction of the kidney, 11.0, 11.25 and Immunohistochemistry was performed on 6 mm paraffin-embedded sections from 4% paraformaldehyde-fixed 11.25-11.75 dpc embryos using antisera specific for Smads 1 (Santa Cruz, sc-6201), 2 (sc-6200), 3 (Zymed 51-1500), 4 (sc-1909), 5 (sc-7443) and 8 (sc-7442). Smad 1 is weakly expressed in the metanephric blastema at 11.25 dpc (D). Prior to this time-point, no expression can be seen (A). At 11.75 dpc, expression of Smad 1 can be seen in the metanephric blastema, but is excluded from the condensing mesenchyme surrounding the tips of the ureteric bud branches. Weak expression of Smad 2 can be seen in the metanephric blastema at 11.0 dpc (B), and increases in intensity by 11.25 dpc (E). At 11.75 dpc, expression of Smad 2 is seen in the metanephric blastema, and is excluded from the condensing mesenchyme (H). Smad 4 is expressed in the metanephric blastema at 11.0 dpc (C) and 11.25 dpc (F). At 11.75 dpc, expression of Smad 4 is excluded from condensing mesenchyme (I). Expression of Smads 3, 5 and 8 could not be detected prior to 11.75 dpc. At this time, Smad 3 is expressed in cells of both the metanephric blastema and ureteric bud (J). Smads 5 (K) and 8 (L) are expressed weakly, and can be detected only in the metanephric blastema. MB, metanephric blastema; WD, Wolffian duct; UB, ureteric bud; CM, condensing mesenchyme. 11.75 dpc embryos were analyzed. Smad 4 and low levels of Smad 2 can be seen in the metanephric blastema at 11.0 dpc, prior to ingrowth of the ureteric bud and induction of the mesenchyme (Fig. 1) . Smads 1-4 are expressed from 11.25 dpc onwards. As the mesenchyme condenses around the tips of the ureteric bud, Smad activity is markedly downregulated and little, if any, Smad protein is detectable within the condensates, indicating that Smads are coordinately down-regulated upon induction of the mesenchyme. The ureteric bud appears devoid of Smads up to 11.75 dpc. To confirm these data, mRNA expression analysis was performed by reverse transcription-polymerase chain reaction (RT-PCR) (Table 1 ) on separated 11.5 dpc metanephric mesenchymes and ureteric buds (Fig. 2) . Expression of all Smads can be detected in the mesenchyme, but not in the ureteric bud, with the exception of Smad 1. In the 15.5 dpc kidney, Smad expression is coordinate (Fig. 3) . At this stage of development, a cross-section of developmental structures can be seen; several rounds of branching of the ureteric tree have occurred, and tips of the collecting ducts have induced mesenchyme to condense, epithelialize and form renal vesicles, comma and S-shaped bodies and nephric tubules. The glomerulus is formed at the proximal end of this structure with contributions of extrinsic endothelial and pericyte (mesangial) cells. At this stage of nephrogenesis, the peripheral stromal layer is visible. Sites of Smad expression include the peripheral stroma, medullary stroma, collecting ducts, mature glomeruli and proximal tubules. However, as seen at earlier stages, expression is down-regulated in the condensing nephrogenic mesenchyme, and is excluded from renal vesicles, comma and Sshaped bodies. In order to verify the sites of expression, marker analysis was performed. Sections were analyzed by in situ hybridization for expression of WT1 (Armstrong et al., 1993) , a marker for condensing mesenchyme and glomerular podocytes, and Foxd1 (BF2) (Hatini et al., 1996) , a marker for stromal cells, and compared to a section stained for Smad 4. As shown in Fig. 4A , expression of Smad 4 overlaps with Foxd1, and is absent from areas expressing WT1. This confirms that Smad expression is localized to the peripheral stroma of the kidney, and excluded from mesenchymal condensates. To determine which segment of the developing tubule expresses Smads, serial sections were stained using the lotus tetragonolobus agglutinin (LTA) and the Smad 4 Fig. 2 . RT-PCR analysis of separated mesenchymes and ureteric buds from 11.5 dpc kidneys. Metanephric mesenchyme (MM) and ureteric bud (UB) RNA was prepared. In order to assay for presence of RNA in each RNA pool, RT-PCR specific for the hypoxanthine phosphoribosyltransferase (HPRT) transcript was performed. Also, in order to confirm that there was no contamination of ureteric bud RNA with mesenchyme, RT-PCR was performed to detect the mesenchyme-specific Wilms tumor (WT) transcript. RT-PCRs specific for Smads 1-8 demonstrate the presence of all Smads assayed in the metanephric mesenchyme. Only a low level of Smad 1 is detected in the ureteric bud. The presence of Smad 1 RNA in the ureteric bud, in the absence of detectable protein could reflect a level of expression below the detection limit of immunohistochemistry. However, post-transcriptional regulation, leading to degradation of Smad 1 mRNA prior to translation cannot be ruled out. Standard PCR amplification conditions were used with the primers listed in Table 1 . Fig. 3 . Expression of Smads 1-5 and 8 in the kidney at 15.5 dpc. Expression of Smad 1 is seen in the peripheral stroma, glomeruli and tubules of the kidney and weakly in collecting ducts. Smad 2 can be detected in peripheral stroma, glomeruli and tubules, collecting ducts and medullary stroma. Expression of Smad 3 is scattered, with cells of the collecting ducts, glomeruli, tubules and medullary stroma consistently showing staining. Smad 4 is expressed in peripheral stroma, glomeruli, tubules, collecting ducts and medullary stroma. Smads 5 and 8 are very weakly expressed in tubules and collecting ducts. Insets in (A-D) show higher magnifications of structures seen at the periphery of the kidney, demonstrating the absence of Smad expression in condensing mesenchyme and mesenchymal derivatives such as renal vesicles and comma-and S-shaped bodies. ps, peripheral stroma; cm, condensing mesenchyme; cd, collecting duct; ms, medullary stroma; rv, renal vesicle; cb, comma-shaped body; sb, S-shaped body; g, glomerulus; t, tubule. Fig. 4 . Marker analysis of domains of Smad expression in the 15.5 dpc kidney. Sections of 15.5 dpc kidneys were stained for expression of markers specific for various cell populations of the kidney and compared to sections stained with antiserum detecting Smad 4. In situ hybridization (Belo et al., 1997) with probes specific for the Wilms tumor (WT1) (Armstrong et al., 1993 ) and brain factor 2 (BF2) (Hatini et al., 1996) transcripts was performed in order to confirm which cell population within the periphery of the kidney expresses Smad 4. WT1 marks condensing mesenchyme, but is excluded from collecting ducts and peripheral stroma (B). BF2 marks peripheral stroma, and is excluded from condensing mesenchyme and collecting ducts (C). Smad 4 expression (A) overlaps with that of BF2, verifying that Smad 4 is expressed within the peripheral stroma. In order to define the site of expression of Smad 4 within the glomerulus, sections were immunostained using antibodies specific for alpha smooth muscle actin (aSMA) (Sigma Aldrich A2537) (E), a marker for the mesangial cell population, and CD31 (ICN Biochemicals 67337) (F), an endothelial cell marker. Smad 4 expression (D) overlaps with that of aSMA but not CD31, indicating that mesangial cells express Smad 4 and endothelial cells do not. To define the segment of the nephric tubule in which Smads are expressed, Smad 4 staining (G) was compared to staining with lotus tetragonolobus agglutinin (LTA) (Vector Laboratories) (H) on serial sections. LTA lectin stains the proximal segment of the nephric tubule strongly, and also binds with weak affinity to collecting duct epithelium. Smad 4 expression overlaps with LTA staining, demonstrating that Smad 4 is expressed in the proximal tubule. Fig. 5 . Smad 4 and BMP7 expression in lithium chloride treated metanephric mesenchyme explants. Metanephric mesenchyme explants were cultured in vitro for 48 h (Godin et al., 1998) . Explants cultured in the absence of the heterologous inducer lithium chloride degenerated (A), whereas treated mesenchyme survived and formed condensates (B, C). Immunohistochemical analysis shows that Smad 4 expression is down-regulated in condensates (E, F). A b-gal stained mesenchyme explant derived from a mouse expressing LacZ from the BMP7 locus (Godin et al., 1998) antibody. LTA binds strongly to the ciliated epithelium of the proximal tubule, and also weakly to the collecting duct epithelium (Laitinen et al., 1987) . As can be seen in Fig.  4B , Smad 4 and LTA staining overlap, demonstrating that Smads are expressed in the proximal tubule of the nephron, but excluded from the distal tubule. In order to ascertain the precise localization of Smad expression within the glomerulus, sections were stained with antibodies against platelet endothelial cell adhesion marker 1 (CD31) and alpha smooth muscle actin (aSMA). CD31 is expressed on embryonic endothelial cells (Drake and Fleming, 2000) , whereas aSMA is expressed along arteriolar walls and in the mesangial cells of the glomerulus (Lindahl et al., 1998) . Expression of Smads in the glomerulus overlaps with that of aSMA, and is distinct from that of CD31 (Fig. 4D-F) , indicating that Smads are expressed in the mesangial cells of the glomerulus and excluded from the capillary tuft and podocytes. This expression pattern contrasts with that of BMPs 4 and 7, which are expressed in Bowman's capsule and the podocyte layer, respectively.
We utilized an in vitro model system to further define at what stage in the inductive process Smad expression is down-regulated. Lithium chloride is a potent inducer of mesenchyme, leading to condensation, but not complete epithelialization (Davies and Garrod, 1995) . As shown in Fig. 5 , Smad 4 expression is regulated concomitantly with condensation of the mesenchyme after 48 h of lithium chloride treatment, indicating that this event occurs at an early stage of induction. BMP7 has previously been shown to be up-regulated in areas of mesenchymal condensation (Godin et al., 1998) . This expression domain is unique for BMP7 and absence of the ligand from this population of cells has been proposed to be central to the kidney defects seen in BMP7-deficient mice (Dudley and Robertson, 1997) . To determine whether BMP7 up-regulation is synchronized with down-regulation of Smads, we performed a comparison of Smad 4 immunohistochemistry with BMP7 expression, assayed using the BMP7 lacZ reporter mouse strain. This revealed that Smad expression indeed is down-regulated as BMP7 expression is up-regulated within the condensates (Fig. 5) . The switch between BMP responsiveness, and BMP production at this timepoint in mesenchymal induction suggests that signaling through the Smad pathway is incompatible with differentiation of mesenchyme, and that BMP expression from the condensates may signal adjacent mesenchyme in a paracrine manner.
